newsfilter
← Latest News
GlobeNewswire·

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA